CYP19A1 and breast cancer: ORs were not significant and were generally similar in magnitude and direction for analyses restricted to ER+ breast cancer (data not shown), except that the OR estimates were no longer greater than one for the CYP19 rs10046 TT and rs4775936 AA genotypes.